Taxus Cardium Pharmaceuticals is an advanced regenerative therapeutics company which is focused on the development of new and innovative products based on its core gene therapy, manufacturing process and technology platforms for cardiovascular disease, wound healing and tissue engineering.
Generx (alferminogene tadenovec) [Ad5FGF-4], Cardium’s lead Phase 3 clinical study product candidate is a disease-modifying angiogenic growth factor gene therapeutic designed to promote cardiac microvascular circulation to enhance myocardial perfusion (blood flow) for patients with Advanced Angina who are unresponsive to optimal medical therapy and are considered not suitable for coronary artery bypass surgery and angioplasty and stenting.
Excellagen is an FDA-cleared syringe-based flowable topical gel that promotes the activation of the healing process for the treatment of dermal wounds. It is designed to accelerate granulation tissue growth in non-healing wounds and has been demonstrated to activate platelets, triggering the localized release of endogenous growth factors including Platelet-Derived Growth Factor (PDGF), a key biologic mediator of wound healing.
LifeAgain Insurance Solutions is an advanced medical data analytics business focused on the development, marketing and sale of “survivable risk” term life insurance programs for cancer survivors or others with medical conditions who are currently considered uninsurable based on traditional underwriting standards. LifeAgain recently launched its initial BlueMetric Select term life insurance program, underwritten by Symetra Life Insurance, for men with active localized prostate cancer.